Clinical Trial Update: Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

View source ↗

Summary

A clinical trial assessing the impact of Targeted Lung Denervation for severe to very severe COPD has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Targeted Lung Denervation (TLD) system

Snippet

Sponsor: Nuvaira, Inc. | Conditions: COPD | Status: WITHDRAWN